Becton, Dickinson & Co. (NYSE:BDX)

Total revenues experienced a significant upward trajectory over the six-year period from 2016 to 2021, increasing from 12,483 million US dollars to 20,248 million US dollars. While a marginal decline occurred in 2017 and a slight stagnation was noted in 2020, the overall growth trend remained positive, characterized by substantial expansions in 2018 and 2021.

Medical Segment Performance

The Medical segment consistently served as the primary revenue driver. After a slight decrease in 2017 to 7,419 million US dollars, the segment recovered and grew to 9,479 million US dollars by 2021. This segment demonstrates a pattern of steady, moderate growth, maintaining its position as the largest contributor to total revenue.

Life Sciences Segment Expansion

Life Sciences revenues grew from 3,829 million US dollars in 2016 to 6,530 million US dollars in 2021. Growth remained gradual between 2016 and 2019, followed by a notable acceleration between 2020 and 2021, where revenues increased from 4,675 million to 6,530 million US dollars.

Interventional Segment Growth

The Interventional segment exhibited the most dramatic shift in scale. Revenues remained stagnant between 2016 and 2017, hovering around 688 million US dollars, before surging to 3,037 million US dollars in 2018. This upward trajectory continued through 2021, reaching 4,239 million US dollars, representing a fundamental change in the segment's contribution to the overall revenue mix.

Aggregate Revenue Analysis

The overall increase in total revenues was heavily influenced by the rapid scaling of the Interventional segment starting in 2018 and the late-period acceleration of the Life Sciences segment. By 2021, the diversification of revenue streams became more pronounced, with all three segments contributing significantly to the 20,248 million US dollar total.